Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Lintott

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Drugs & Aging|November 1, 1992
HMG-CoA reductase inhibitor use in the aged. A review of clinical experienceC J Lintott, R S Scott
The New Zealand Medical Journal|March 24, 1993
Noninsulin dependent diabetes mellitusC M Florkowski, C J Lintott, R S Scott
The New Zealand Medical Journal|November 27, 1991
Simvastatin and side effectsR S Scott, C J Lintott, M J Wilson
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity|April 1, 1994
Dexfenfluramine reduces cardiovascular risk factorsJ M Bremer, R S Scott, C J Lintott
Australian and New Zealand Journal of Medicine|August 1, 1991
Oat bran and cholesterol reduction: evidence against specific effectJ M Bremer, R S Scott, C J Lintott
Current Medical Research and Opinion|January 1, 1989
Treatment of hyperlipidaemia with acipimoxC J Lintott, R S Scott, J M Bremer
The New Zealand Medical Journal|November 25, 1987
Hyperlipidaemia and the prevention of coronary heart diseaseR S Scott, C J Lintott, J Bremer, et al.
Atherosclerosis|November 1, 1985
Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatmentE D Janus, S Grant, C J Lintott, et al.
Australian and New Zealand Journal of Medicine|August 1, 1993
Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatinC J Lintott, R S Scott, W H Sutherland, et al.
The New Zealand Medical Journal|June 22, 1988
Reducing hyperlipidaemiaR S Scott, E R Nye, C J Lintott, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Drugs & Aging|November 1, 1992
HMG-CoA reductase inhibitor use in the aged. A review of clinical experienceC J Lintott, R S Scott
The New Zealand Medical Journal|March 24, 1993
Noninsulin dependent diabetes mellitusC M Florkowski, C J Lintott, R S Scott
The New Zealand Medical Journal|November 27, 1991
Simvastatin and side effectsR S Scott, C J Lintott, M J Wilson
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity|April 1, 1994
Dexfenfluramine reduces cardiovascular risk factorsJ M Bremer, R S Scott, C J Lintott
Australian and New Zealand Journal of Medicine|August 1, 1991
Oat bran and cholesterol reduction: evidence against specific effectJ M Bremer, R S Scott, C J Lintott
Current Medical Research and Opinion|January 1, 1989
Treatment of hyperlipidaemia with acipimoxC J Lintott, R S Scott, J M Bremer
The New Zealand Medical Journal|November 25, 1987
Hyperlipidaemia and the prevention of coronary heart diseaseR S Scott, C J Lintott, J Bremer, et al.
Atherosclerosis|November 1, 1985
Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatmentE D Janus, S Grant, C J Lintott, et al.
Australian and New Zealand Journal of Medicine|August 1, 1993
Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatinC J Lintott, R S Scott, W H Sutherland, et al.
The New Zealand Medical Journal|June 22, 1988
Reducing hyperlipidaemiaR S Scott, E R Nye, C J Lintott, et al.
Pageof 2